ID Biomedical Sues Third Wave for Patent Infringement | GenomeWeb

NEW YORK, Sept. 15 - ID Biomedical (Nasdaq: IDBE) of Vancouver said Friday that it had filed a patent infringement suit against Third Wave Technologies of Madison, Wis., for its use of a patented nucleic acid amplification and detection technology.

The Canadian company claimed that Third Wave’s Invader assay products and technology violate elements of US Patent 5,403,711, which is exclusively licensed to ID Biomedical.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.